These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12455152)

  • 1. Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine.
    Haller H; Cosentino F; Lüscher TF
    Drugs R D; 2002; 3(5):311-23. PubMed ID: 12455152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA).
    Zanchetti A
    J Hypertens Suppl; 1995 Dec; 13(4):S35-9. PubMed ID: 8824685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lacidipine: a review of its use in the management of hypertension.
    McCormack PL; Wagstaff AJ
    Drugs; 2003; 63(21):2327-56. PubMed ID: 14524737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiatherosclerotic effects of calcium antagonists.
    Paoletti R; Bernini F; Corsini A; Soma MR
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S6-10. PubMed ID: 8852538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium antagonists and atherosclerosis protection in hypertension.
    Hernández RH; Armas-Hernández MJ; Velasco M; Israili ZH; Armas-Padilla MC
    Am J Ther; 2003; 10(6):409-14. PubMed ID: 14624278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
    Zanchetti A; Bond MG; Hennig M; Neiss A; Mancia G; Dal Palù C; Hansson L; Magnani B; Rahn KH; Reid JL; Rodicio J; Safar M; Eckes L; Rizzini P;
    Circulation; 2002 Nov; 106(19):2422-7. PubMed ID: 12417537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of the nitric oxide system in the anti-atherosclerotic potential of lacidipine in the ApoE-deficient mouse: a morphological, functional, and electrochemical study.
    Cristofori PG; Crivellente FA; Faustinelli I; Lanzoni AR; Lazzarini C; Vecchiato E; Andreoli M; Turton JA; Zancanaro C; Crespi FM
    Toxicol Pathol; 2004; 32(4):493-9. PubMed ID: 15223775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.
    Zanchetti A; Hennig M; Baurecht H; Tang R; Cuspidi C; Carugo S; Mancia G
    J Hypertens; 2007 Dec; 25(12):2463-70. PubMed ID: 17984668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The preliminary clinical evidence from the ELSA study. The European Lacidipine Study on Atherosclerosis].
    Leonetti G
    Ann Ital Med Int; 1995 Oct; 10 Suppl():74S-77S. PubMed ID: 8562272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse.
    Cristofori P; Lanzoni A; Quartaroli M; Pastorino AM; Zancanaro C; Cominacini L; Gaviraghi G; Turton J
    J Hypertens; 2000 Oct; 18(10):1429-36. PubMed ID: 11057430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.
    Zanchetti A; Bond MG; Hennig M; Neiss A; Mancia G; Dal Palù C; Hansson L; Magnani B; Rahn KH; Reid J; Rodicio J; Safar M; Eckes L; Ravinetto R
    J Hypertens; 1998 Jul; 16(7):949-61. PubMed ID: 9794735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation.
    Cristofori P; Crivellente F; Campagnola M; Pasini AF; Garbin U; Rigoni A; Tosetti M; Turton J; Faustinelli I; Cominacini L
    Int J Exp Pathol; 2004 Apr; 85(2):105-14. PubMed ID: 15154916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Third generation of calcium antagonists: focus on lacidipine].
    Sidorenko BA; Stetsenko TM; Preobrazhenskiĭ DV; Savchenko MV; Soplevenko AV; Shabaeva EN
    Kardiologiia; 2002; 42(12):81-90. PubMed ID: 12494025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound protocol and quality control procedures in the European Lacidipine Study on Atherosclerosis (ELSA).
    Mercuri M; Tang R; Phillips RM; Bond MG
    Blood Press Suppl; 1996; 4():20-3. PubMed ID: 8973778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-atherosclerotic activity of the calcium antagonist lacidipine in cholesterol-fed hamsters.
    Cristofori P; Lanzoni A; Gaviraghi G; Turton J; Sbarbati A
    Biomed Pharmacother; 2000 Mar; 54(2):93-9. PubMed ID: 10759293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lacidipine on the carotid intimal hyperplasia induced by cuff injury.
    Soma MR; Donetti E; Parolini C; Barberi L; Paoletti R; Fumagalli R; Catapano AL
    J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S71-4. PubMed ID: 7609512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits.
    Soma MR; Donetti E; Seregni R; Barberi L; Fumagalli R; Paoletti R; Catapano AL
    Br J Pharmacol; 1996 May; 118(2):215-9. PubMed ID: 8735617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.
    Lee CR; Bryson HM
    Drugs; 1994 Aug; 48(2):274-96. PubMed ID: 7527328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of lacidipine, a vascular-selective calcium antagonist.
    Micheli D; Ratti E; Toson G; Gaviraghi G
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S1-8. PubMed ID: 1725998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential modification of plaque behavior through the European lacidipine study on atherosclerosis.
    Bond MG; Mercuri M
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S11-6. PubMed ID: 8852539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.